

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3048866

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CONFIRMATORY ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NOVARTIS VACCINES AND DIAGNOSTICS, INC.	08/26/2014
NOVARTIS AG	08/26/2014

RECEIVING PARTY DATA

Name:	NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Street Address:	IP SERVICES BLDG. 433 257
Internal Address:	ONE HEALTH PLAZA
City:	EAST HANOVER
State/Country:	NEW JERSEY
Postal Code:	07936-1080
Name:	NOVARTIS AG
Street Address:	LICHTSTRASSE 35
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4056
Name:	GRIFOLS WORLDWIDE OPERATIONS LIMITED
Street Address:	EMBASSY HOUSE
Internal Address:	BALLSBRIDGE
City:	DUBLIN 4
State/Country:	IRELAND
Postal Code:	D4

PROPERTY NUMBERS Total: 45

Property Type	Number
Patent Number:	6692907
Patent Number:	6121020
Patent Number:	6458527
Patent Number:	7273695
Patent Number:	6531276
Patent Number:	7408053
Patent Number:	7425428
Patent Number:	7285271

PATENT

Property Type	Number
Patent Number:	5688688
Patent Number:	7205101
Patent Number:	6013432
Patent Number:	7527925
Patent Number:	7442525
Patent Number:	RE41158
Patent Number:	7018984
Patent Number:	5922857
Patent Number:	6057093
Patent Number:	5714596
Patent Number:	5863719
Patent Number:	6074816
Patent Number:	5712088
Patent Number:	6096541
Patent Number:	7790366
Patent Number:	6171782
Patent Number:	6027729
Patent Number:	5679342
Patent Number:	5968775
Patent Number:	5597691
Patent Number:	5683864
Patent Number:	6312889
Patent Number:	5712087
Patent Number:	6346375
Patent Number:	6150087
Patent Number:	6274148
Patent Number:	5756312
Patent Number:	5728520
Patent Number:	5766845
Patent Number:	5670152
Patent Number:	5670153
Patent Number:	6190864
Patent Number:	6214583
Patent Number:	6071693
Patent Number:	6297370
Patent Number:	7097987
Patent Number:	5851759

CORRESPONDENCE DATA

PATENT

REEL: 033886 FRAME: 0314

Fax Number: (617)871-4708

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 617-871-8017

Email: nvd.maildata@novartis.com

Correspondent Name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Address Line 1: IP SERVICES BLDG. 433 257

Address Line 2: ONE HEALTH PLAZA

Address Line 4: EAST HANOVER, NEW JERSEY 07936-1080

ATTORNEY DOCKET NUMBER:	GRIFOLS - CO-OWNED
--------------------------------	--------------------

NAME OF SUBMITTER:	KATHLEEN M. BASTARACHE
---------------------------	------------------------

SIGNATURE:	/Kathleen M. Bastarache/
-------------------	--------------------------

DATE SIGNED:	10/02/2014
---------------------	------------

Total Attachments: 9

source=Grifols_CoOwned#page1.tif

source=Grifols_CoOwned#page2.tif

source=Grifols_CoOwned#page3.tif

source=Grifols_CoOwned#page4.tif

source=Grifols_CoOwned#page5.tif

source=Grifols_CoOwned#page6.tif

source=Grifols_CoOwned#page7.tif

source=Grifols_CoOwned#page8.tif

source=Grifols_CoOwned#page9.tif

CONFIRMATORY ASSIGNMENT

This Confirmatory Assignment Agreement is entered into by and between Novartis Vaccines and Diagnostics, Inc., a Delaware corporation (“**NVD Inc.**”) and Novartis AG, a company limited by shares (*Aktiengesellschaft*) pursuant to art. 620 ff. CO having its seat in Basel (together with NVD Inc., “**Assignors**”), on the one hand, and Grifols Worldwide Operations Limited, a company organized under the laws of the Republic of Ireland (“**Grifols**”), on the other hand.

Assignors and Grifols previously entered into an Intellectual Property Assignment and Agreement dated January 9, 2014 (the “**IP Assignment Agreement**”) whereby Assignors agreed to assign, transfer, convey and deliver to Grifols an undivided one-half ownership interest in and to the patents and patent applications on the attached Schedule. All capitalized terms that are not expressly defined herein have the definition provided in the IP Assignment Agreement.


For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, effective as of January 10, 2014 (the “**Effective Date**”) and subject to the terms and conditions of the IP Assignment Agreement (including, without limitation, Sections 2.1 and 2.2), each Assignor hereby assigns, transfers, conveys and delivers, and shall cause each of its relevant Affiliates to, assign, transfer, convey and deliver to Grifols, and its successors and assigns, absolutely and forever, and Grifols hereby accepts the assignment, transfer, conveyance and delivery of an undivided one-half ownership interest in and to the patents and patent applications listed in the attached Schedule.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the state of New York, including all matters of construction, validity and performance, in each case without reference to any conflict of law rules that might lead to the application of the laws of any other jurisdiction.

[Signatures begin on the next page]

AS WITNESS the signature of duly authorized officers of the parties hereto

Signed for and behalf of)
Novartis Vaccines and) 
Diagnostics, Inc.) Name: Helen Lee

Capacity: Assistant Secretary

Date: 21 August 2014

Witness Signature: 

Print Witness Name: Colleen McKiernan

Witness Address: 350 Massachusetts Ave, Cambridge, MA USA 02139

Signed for and behalf of)
Novartis AG) 
Name: Marco Riensche


Capacity: Authorized Signatory

Date: 26 August, 2014

Witness Signature: 


Print Witness Name: Colleen McKiernan

Witness Address: 350 Massachusetts Ave, Cambridge, MA USA 02139

Signed for and behalf of)
Novartis AG) 
Name: Beth O'Brien

Capacity: Authorized Signatory

Date: 26 August 2014

Witness Signature: 

Print Witness Name: Colleen McKiernan

Witness Address: 350 Massachusetts Ave, Cambridge, MA USA 02139

Signed for and behalf of
Grifols Worldwide
Operations Limited


) 
)

) Name: Javier Jorba Ribes

Capacity: Director

Date: 18/09/2014

Witness Signature:


.....

Print Witness Name:

Carme Casamor Baules
.....

Witness Address:

Pol. Levante-C / Can Gussch, 2
08150 Parets del Vallès Barcelona - Spain
.....

Case Reference	Internal Title	Country	Current Status	Filing	Filing Number	Granted	Grant Number
PAT050956-US-DIV02	CONSERVED MOTIF OF HEPATITIS C VIRUS E2/NS1 REGION	United States of America	Granted	9-May-1995	08/437943	17-Feb-2004	6692907
PAT050966-US-CNT02	NOVEL HEPATITIS C E1 AND E2 TRUNCATED POLYPEPTIDES AND METHODS OF OBTAINING THE SAME	United States of America	Granted	24-Mar-1997	08/824057	19-Sep-2000	6121020
PAT051015-CA-NP01	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	Canada	Granted	28-Oct-1985	617159	10-May-2005	1341482
PAT051015-CA-NP02	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	Canada	Granted	28-Oct-1985	494006	4-Mar-2003	1341423
PAT051015-US-CNT01	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	United States of America	Granted	28-Jun-1993	08/083391	1-Oct-2002	6458527
PAT051015-US-CNT02	HIV IMMUNOASSAYS USING SYNTHETIC ENVELOPE POLYPEPTIDES	United States of America	Granted	8-Jul-1993	08/089407	25-Sep-2007	7273695
PAT051015-US-CNT03	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	United States of America	Granted	14-Mar-1995	08/403588	11-Mar-2003	6531276
PAT051015-US-CNT04	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	United States of America	Granted	17-May-1995	08/442750	5-Aug-2008	7408053
PAT051015-US-CNT05	RECOMBINANT DNA CONSTRUCT FOR HIV ENVELOPE POLYPEPTIDES AND POLYPEPTIDES PRODUCED THEREBY	United States of America	Granted	17-May-1995	08/443077	16-Sep-2008	7425428
PAT051015-US-CNT07	HUMAN IMMUNODEFICIENCY VIRUS (HIV) NUCLEOTIDE SEQUENCES, RECOMBINANT POLYPEPTIDES, AND APPLICATIONS THEREOF	United States of America	Granted	31-May-1995	08/456024	23-Oct-2007	7285271
PAT051015-US-DIV04	A VECTOR FOR EXPRESSION OF A POLYPEPTIDE IN A MAMMALIAN CELL	United States of America	Granted	10-Aug-1994	08/288336	18-Nov-1997	5688688
PAT051015-US-DIV06	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	United States of America	Granted	17-May-1995	08/442748	17-Apr-2007	7205101

Case Reference	Internal Title	Country	Current Status	Filing	Filing Number	Granted	Grant Number
PAT051015-US-DIV07	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	United States of America	Granted	17-May-1995	08/443434	11-Jan-2000	6013432
PAT051015-US-DIV08	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	United States of America	Granted	17-May-1995	08/443433	5-May-2009	7527925
PAT051015-US-DIV09	A METHOD FOR EXPRESSING HIV POLYPEPTIDES	United States of America	Granted	17-May-1995	08/443118	28-Oct-2008	7442525
PAT051015-US-REI	Polynucleotide Sequences of Viruses Associated with Lymphadenopathy Syndrome and/or Acquired Immune Deficiency Svndrome	United States of America	Granted	12-Jan-2009	12/352068	2-Mar-2010	RE41158
PAT051015-US-REX	VECTOR FOR EXPRESSION OF A POLYPEPTIDE IN A MAMMALIAN CELL	United States of America	Granted	25-Apr-2006	90/008017	22-Dec-2009	5688688
PAT051022-US-CNT	METHODS AND COMPOSITIONS FOR CONTROLLING TRANSLATION OF HCV PROTEINS	United States of America	Granted	6-Jun-1995	08/477895	28-Mar-2006	7018984
PAT051022-US-DIV01	METHODS AND COMPOSITIONS FOR CONTROLLING TRANSLATION OF HCV PROTEINS	United States of America	Granted	12-May-1995	08/440209	13-Jul-1999	5922857
PAT051022-US-DIV02	METHODS AND COMPOSITIONS FOR CONTROLLING TRANSLATION OF HCV PROTEINS	United States of America	Granted	12-May-1995	08/439996	2-May-2000	6057093
PAT051030-AR-DIV	NANBV Diagnostics and Vaccines	Argentina	Granted	10-Jun-1992	322506	31-May-2006	AR256192V1
PAT051030-CA-NP01	NANBV Diagnostics and Vaccines	Canada	Granted	18-Nov-1988	583561	8-May-2012	1341629
PAT051030-KR-PCTD	NANBV Diagnostics and Vaccines	South Korea / Republic of Korea	Granted	22-Jul-1997	10-1997-0704975	26-May-1999	216013
PAT051030-PH-DIV	NANBV Diagnostics and Vaccines	Philippines	Granted	19-Sep-1991	43138	12-Jun-2007	1-1991-43138
PAT051030-PH-DIV01	NANBV Diagnostics and Vaccines	Philippines	Granted	19-Sep-1991	43139	31-Jul-1997	30572
PAT051030-PH-DIV02	NANBV Diagnostics and Vaccines	Philippines	Granted	16-Mar-1990	1-2003-000220	23-Dec-2004	1-2003-000220
PAT051030-PH-DIV03	NANBV Diagnostics and Vaccines	Philippines	Granted	19-Sep-1991	43144	12-Jun-2007	1-1991-43144
PAT051030-PH-DIV04	NANBV Diagnostics and Vaccines	Philippines	Granted	16-Mar-1990	1-2003-000219	23-Dec-2004	1-2003-000219
PAT051030-PH-DIV05	NANBV Diagnostics and Vaccines	Philippines	Granted	19-Sep-1991	43145	12-Jun-2007	1-1991-43145
PAT051030-PH-DIV06	NANBV Diagnostics and Vaccines	Philippines	Granted	19-Sep-1991	43140	12-Jun-2007	1-1991-43140
PAT051030-PH-NP	NANBV Diagnostics and Vaccines	Philippines	Granted	18-Nov-1988	37833	12-Jun-2007	1-1988-37833
PAT051030-PH-NP01	NANBV Diagnostics and Vaccines	Philippines	Granted	16-Mar-1990	40217	23-Dec-2004	1-1990-40217
PAT051030-US-CNT01	NANBV Diagnostics and Vaccines	United States of America	Granted	31-Mar-1993	08/040564	3-Feb-1998	5714596
PAT051030-US-CNT04	NANBV Diagnostics and Vaccines	United States of America	Granted	7-Jun-1995	08/472821	26-Jan-1999	5863719

PATENT

REEL: 033886 FRAME: 0320

Case Reference	Internal Title	Country	Current Status	Filing	Filing Number	Granted	Grant Number
PAT051030-US-DIV01	NANBV Diagnostics and Vaccines	United States of America	Granted	16-Sep-1994	08/307273	13-Jun-2000	6074816
PAT051030-US-DIV02	NANBV Diagnostics and Vaccines	United States of America	Granted	15-May-1995	08/440769	27-Jan-1998	5712088
PAT051030-US-DIV04	NANBV Diagnostics and Vaccines	United States of America	Granted	15-May-1995	08/441026	1-Aug-2000	6096541
PAT051030-US-DIV05	NANBV Diagnostics and Vaccines	United States of America	Granted	15-May-1995	08/441443	7-Sep-2010	7790366
PAT051030-US-DIV06	NANBV Diagnostics and Vaccines	United States of America	Granted	15-May-1995	08/442647	9-Jan-2001	6171782
PAT051030-US-DIV07	NANBV Diagnostics and Vaccines	United States of America	Granted	15-May-1995	08/440755	22-Feb-2000	6027729
PAT051043-US-CIP02	Methods for culturing HCV in B- or T- lymphocyte cell lines	United States of America	Granted	27-Jul-1993	08/097853	21-Oct-1997	5679342
PAT051043-US-CNT	HEPATITIS C VIRUS INFECTED CELL SYSTEMS	United States of America	Granted	10-May-1995	08/438435	19-Oct-1999	5968775
PAT051047-AU-PCT	HCV NS3 PROTEIN FRAGMENTS HAVING HELICASE ACTIVITY AND IMPROVED SOLUBILITY	Australia	Granted	12-Sep-1996	72384/96	20-Jul-2000	717875
PAT051047-CA-PCT02	HCV NS3 PROTEIN FRAGMENTS HAVING HELICASE ACTIVITY AND IMPROVED SOLUBILITY	Canada	Granted	12-Sep-1996	2226293	30-Jul-2002	2226293
PAT051047-EP-EPT02	HCV NS3 PROTEIN FRAGMENTS HAVING HELICASE ACTIVITY AND IMPROVED SOLUBILITY	European Procedure	Pending	12-Sep-1996	96933781.5		
PAT051047-IL-PCT	HCV NS3 PROTEIN FRAGMENTS HAVING HELICASE ACTIVITY AND IMPROVED SOLUBILITY	Israel	Granted	12-Sep-1996	123248	25-Oct-2007	123248
PAT051047-NZ-PCT	HCV NS3 PROTEIN FRAGMENTS HAVING HELICASE ACTIVITY AND IMPROVED SOLUBILITY	New Zealand	Granted	12-Sep-1996	319786	12-May-2000	319786
PAT051047-US-DIV02	Hepatitis C Virus Proteases	United States of America	Granted	12-May-1995	08/440548	28-Jan-1997	5597691
PAT051048-PH-NP	COMBINATIONS OF HEPATITIS C VIRUS (HCV) ANTIGENS FOR USE IN IMMUNOASSAYS FOR ANTI-HCV ANTIBODIES	Philippines	Granted	3-Apr-1991	42245	19-Jun-2001	1-1991-42245
PAT051048-US-CIP	COMBINATIONS OF HEPATITIS C VIRUS (HCV) ANTIGENS FOR USE IN IMMUNOASSAYS FOR ANTI-HCV ANTIBODIES	United States of America	Granted	7-Jul-1992	07/910760	4-Nov-1997	5683864

PATENT

REEL: 033886 FRAME: 0321

Case Reference	Internal Title	Country	Current Status	Filing	Filing Number	Granted	Grant Number
PAT051048-US-CNT	COMBINATIONS OF HEPATITIS C VIRUS (HCV) ANTIGENS FOR USE IN IMMUNOASSAYS FOR ANTI-HCV ANTIBODIES	United States of America	Granted	12-May-1995	08/440549	6-Nov-2001	6312889
PAT051048-US-DIV	COMBINATIONS OF HEPATITIS C VIRUS (HCV) ANTIGENS FOR USE IN IMMUNOASSAYS FOR ANTI-HCV ANTIBODIES	United States of America	Granted	12-May-1995	08/440519	27-Jan-1998	5712087
PAT051049-US-PCT	Hepatitis C Virus Epitopes	United States of America	Granted	18-Nov-1988	08/403590	12-Feb-2002	6346375
PAT051049-US-PCTD	Hepatitis C Virus Epitopes	United States of America	Granted	18-May-1995	08/444818	21-Nov-2000	6150087
PAT051058-US-CIP02	Hepatitis C Virus Asialoglycoproteins	United States of America	Granted	26-May-1994	08/249843	14-Aug-2001	6274148
PAT051060-US-CNT01	IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS	United States of America	Granted	19-Apr-1994	08/231368	26-May-1998	5756312
PAT051060-US-CNT02	IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS	United States of America	Granted	6-Jun-1995	08/471498	17-Mar-1998	5728520
PAT051060-US-DIV01	IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS	United States of America	Granted	12-May-1995	08/440210	16-Jun-1998	5766845
PAT051060-US-DIV02	IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS	United States of America	Granted	12-May-1995	08/440103	23-Sep-1997	5670152
PAT051060-US-DIV03	IMMUNOREACTIVE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS	United States of America	Granted	12-May-1995	08/440542	23-Sep-1997	5670153
PAT051061-PT-NP	HCV GENOMIC SEQUENCES FOR DIAGNOSTICS AND THERAPEUTICS	America Portugal	Granted	8-May-1992	100472	3-May-1999	100472
PAT051061-US-CNT01	HCV GENOMIC SEQUENCES FOR DIAGNOSTICS AND THERAPEUTICS	United States of America	Granted	1-Apr-1994	08/221653	20-Feb-2001	6190864
PAT051061-US-DIV01	HCV GENOMIC SEQUENCES FOR DIAGNOSTICS AND THERAPEUTICS	United States of America	Granted	16-May-1995	08/442144	10-Apr-2001	6214583
PAT051061-US-DIV02	HCV GENOMIC SEQUENCES FOR DIAGNOSTICS AND THERAPEUTICS	United States of America	Granted	16-May-1995	08/441971	6-Jun-2000	6071693
PAT051061-US-DIV03	HCV GENOMIC SEQUENCES FOR DIAGNOSTICS AND THERAPEUTICS	United States of America	Granted	16-May-1995	08/441970	2-Oct-2001	6297370
PAT051108-AT-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Austria	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-BE-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Belgium	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-CA-PCT	HEPATITIS C RECEPTOR PROTEIN CD81	Canada	Granted	6-Oct-1998	2304796	3-Dec-2013	2304796
PAT051108-CH-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Switzerland	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-DE-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Germany	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-DK-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Denmark	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-EP-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	European Procedure	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-ES-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Spain	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534

PATENT

REEL: 033886 FRAME: 0322

Case Reference	Internal Title	Country	Current Status	Filing	Filing Number	Granted	Grant Number
PAT051108-FI-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Finland	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-FR-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	France	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-GB-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	United Kingdom	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-GR-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Greece	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-HK-FPR	HEPATITIS C RECEPTOR PROTEIN CD81	Hong Kong	Granted	9-Aug-2000	104953.7	30-Apr-2010	1025793
PAT051108-IE-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Ireland	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-IT-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Italy	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-JP-PCT	HEPATITIS C RECEPTOR PROTEIN CD81	Japan	Granted	6-Oct-1998	2000-514996	10-Oct-2008	4198882
PAT051108-JP-PCTD2	HEPATITIS C RECEPTOR PROTEIN CD81	Japan	Abandoned	4-Jan-2012	2012-122		
PAT051108-LU-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Luxembourg	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-MC-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Monaco	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-NL-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Netherlands	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-PT-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Portugal	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-SE-EPT	HEPATITIS C RECEPTOR PROTEIN CD81	Sweden	Granted	6-Oct-1998	98946642.0	25-Nov-2009	1021534
PAT051108-US-CNT01	HEPATITIS C RECEPTOR PROTEIN CD81	United States of America	Granted	3-Jun-2004	10/859700	29-Aug-2006	7097987
PAT051108-US-CNT04	HEPATITIS C RECEPTOR PROTEIN CD81	United States of America	Abandoned	24-Jun-2011	13/167887		
PAT051421-AT-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Austria	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-BE-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Belgium	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-CA-PCT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Canada	Granted	11-Apr-1997	2251673	25-Oct-2005	2251673
PAT051421-CH-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Switzerland	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-DE-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Germany	Granted	11-Apr-1997	97920354.4	26-Dec-2007	69738419.5
PAT051421-ES-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Spain	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-FR-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	France	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406

Case Reference	Internal Title	Country	Current Status	Filing	Filing Number	Granted	Grant Number
PAT051421-GB-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	United Kingdom	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-IE-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Ireland	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-IT-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Italy	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-NL-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Netherlands	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-SE-EPT	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	Sweden	Granted	11-Apr-1997	97920354.4	26-Dec-2007	904406
PAT051421-US-NP	HETERODUPLEX TRACKING ASSAY (HTA) FOR GENOTYPING HCV	United States of America	Granted	19-Apr-1996	08/634797	22-Dec-1998	5851759